TB is the second deadliest infectious disease next to COVID-19,and the ninth largest cause of death globally.In2020,there were approximately 9.2 million TB patients worldwide,with approximately 1.2 million HIV-negative deaths and approximately 208,000 HIV-positive deaths from tuberculosis.TB treatments are increasingly facing multi-drug resistance problems and the only TB vaccine for adults was only recently approved in China in June 2021.In light of the public health crisis,the WHO and member states have pledged to decrease TB incidence and death rate by 90% and 95%,respectively,by 2035,indicating significant market demand for tuberculosis vaccines.
REC607 -- Adult tuberculosis vector vaccine
- Signed the technology transfer agreement with Shanghai Public Health Clinical Center, and obtained the proprietary technology and patent of REC607 with the exclusive global development right
- A non-replicating Sendai virus vector based on an implant-encoded immune dominant antigen of MYCObacterium tuberculosis
- The project was identified as a major national science and technology special project in 2018